Avior G, Dagan O, Shochat I, et al. - Provided that the 2017 revised Bethesda System for Reporting Thyroid Cytopathology (BSRTC) included new malignancy rates for each category as well as new management recommendations, researchers conducted this retrospective single center case series with chart review to assess the malignancy rate and test performance for BSRTC categories in a middle‐sized institution outside the U.S. Participants in the study were patients who underwent thyroid surgery with a pre‐operative BSRTC between the years 2010 and 2018 at the institution. Three hundred and sixty‐four patients were involved, with an overall malignancy rate of 34.3%. Data reported that the malignancy rate for BSRTC categories I‐VI was: 13.3%, 5.1%, 25.0%, 24.4%, 91.3% and 95.2%, respectively. Findings showed that the revised 2017 BSRTC management recommendations for thyroid nodules are also true in smaller non–US center, promoting their use globally, despite variations from the reported 2017 BSRTC malignancy rates.